Contact
searchSearch
HMP Global
Login

BCMA Test Your Knowledge

Test Your Knowledge
Quiz: How Do Patients With MM Who Received Anti-BCMA Therapy Respond to COVID-19 Vaccinations?
12/01/2021
True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.
True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.
True or false: Patients with MM...
12/01/2021
Oncology
Quiz
Quiz: Which of the Following Inhibitors Target BCMA in MM?
11/10/2021
Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?
Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?
Which of the following...
11/10/2021
Oncology
Test Your Knowledge
Quiz: Is Extramedullary Disease Associated with Poor Prognoses in R/R MM?
11/02/2021
True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.
True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.
True or false: In R/R MM,...
11/02/2021
Oncology
Quiz
Quiz: Can Anti-BCMA CAR-T Cell Therapy Cause Humoral Immune Deficiencies in R/R MM?
10/14/2021
True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.
True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.
True or false: A profound and...
10/14/2021
Oncology
Test Your Knowledge
Quiz: Which Cell Type is Known for BCMA Expression?
09/20/2021
Which of the following cell type is known for BCMA expression?
Which of the following cell type is known for BCMA expression?
Which of the following cell type...
09/20/2021
Oncology
Test Your Knowledge
Quiz: Responses to BCMA-Directed CAR-T Therapy for R/R MM
09/07/2021
True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.
True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.
True or false: Results from the...
09/07/2021
Oncology
Test Your Knowledge
Quiz: Does Teclistamab Therapy Display Promise in BCMA-Positive MM?
11/19/2020
True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.
True or False: Data suggest that...
11/19/2020
Oncology
Test Your Knowledge
Quiz: The Basics of BCMA Expression in Multiple Myeloma
10/08/2020
True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.
True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.
True or False: BCMA is expressed...
10/08/2020
Oncology
Test Your Knowledge
Quiz: Promising Role of BCMA-Directed CAR-T Therapy for R/R MM
09/25/2020
True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.
True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.
True or False: According to data...
09/25/2020
Oncology
Test Your Knowledge
Quiz: Can BCMA-Targeting CAR T-Cells Improve Patient Outcomes in MM?
08/26/2020
True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.
True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.
True or False: Multiple studies...
08/26/2020
Oncology

Recent News

News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use